Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 13-Oct-20 3:54 PM View:  | McDevitt Damien Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 12-Oct-20 | Disposition (change in control) | 242,978 | $18.15 | $4,410,050.00 | (100%) 242.98K to 0 | |
| 13-Oct-20 3:59 PM View: | Jenne Kyle Chief Commercial Officer | Akcea Therapeutics, Inc. (AKCA) | 12-Oct-20 | Disposition (change in control) | 52,012 | $18.15 | $944,018.00 | (100%) 52.01K to 0 | |
| 13-Oct-20 3:58 PM View: | Howarth Alex G. Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 12-Oct-20 | Disposition (change in control) | 66,800 | $18.15 | $1,212,420.00 | (100%) 66.8K to 0 | |
| 13-Oct-20 4:02 PM View: | Patterson Joshua F. General Counsel | Akcea Therapeutics, Inc. (AKCA) | 12-Oct-20 | Disposition (change in control) | 26,532 | $18.15 | $481,556.00 | (100%) 26.53K to 0 | |
| 13-Oct-20 3:56 PM View: | Andrews William T. Chief Medical Officer | Akcea Therapeutics, Inc. (AKCA) | 12-Oct-20 | Disposition (change in control) | 37,500 | $18.15 | $680,625.00 | (100%) 37.5K to 0 | |
| 13-Oct-20 4:04 PM View: | Price Michael Dennis Chief Financial Officer | Akcea Therapeutics, Inc. (AKCA) | 12-Oct-20 | Disposition (change in control) | 50,000 | $18.15 | $907,500.00 | (100%) 50.0K to 0 | |
| 14-Oct-20 4:05 PM View: | Isis Pharmaceuticals Inc 10% Owner | Akcea Therapeutics, Inc. (AKCA) | 10-Oct-20 | Private Purchase | 21,237,700 | $18.15 | $385,464,992.00 | 28% 77.08M to 98.32M | |
| 24-Sep-20 4:25 PM View: | Patterson Joshua F. General Counsel | Akcea Therapeutics, Inc. (AKCA) | 22-Sep-20 | Sale | 319 | $18.12 | $5,780.28 | (1%) 26.85K to 26.53K | |
| 24-Sep-20 4:19 PM View: | McDevitt Damien Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 22-Sep-20 | Sale | 8,709 | $18.12 | $157,807.00 | (3%) 251.69K to 242.98K | |
| 24-Sep-20 4:21 PM View: | Jenne Kyle Chief Commercial Officer | Akcea Therapeutics, Inc. (AKCA) | 22-Sep-20 | Sale | 720 | $18.12 | $13,046.40 | (1%) 52.73K to 52.01K | |
| 02-Sep-20 4:20 PM View: | McDevitt Damien Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 31-Aug-20 | Grant | 1,104 | $14.40 | $15,896.50 | < 1% 250.58K to 251.69K | |
| 20-Jul-20 5:18 PM View: | Patterson Joshua F. General Counsel | Akcea Therapeutics, Inc. (AKCA) | 17-Jul-20 | Sale | 263 | $12.50 | $3,287.79 | (< 1%) 27.11K to 26.85K | |
| 10-Jul-20 5:31 PM View: | Andrews William T. Chief Medical Officer | Akcea Therapeutics, Inc. (AKCA) | 09-Jul-20 | Grant | 37,500 | -- | -- | 100% 0 to 37.5K | |
| 19-May-20 5:41 PM View: | Price Michael Dennis Chief Financial Officer | Akcea Therapeutics, Inc. (AKCA) | 18-May-20 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 15-Apr-20 5:30 PM View: | Patterson Joshua F. General Counsel | Akcea Therapeutics, Inc. (AKCA) | 15-Apr-20 | Grant | 12,500 | -- | -- | 86% 14.61K to 27.11K | |
| 25-Mar-20 4:44 PM View: | Patterson Joshua F. General Counsel | Akcea Therapeutics, Inc. (AKCA) | 23-Mar-20 | Sale | 335 | $11.76 | $3,938.09 | (2%) 14.95K to 14.61K | |
| 25-Mar-20 4:41 PM View: | McDevitt Damien Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 23-Mar-20 | Sale | 9,417 | $11.75 | $110,649.00 | (4%) 255.2K to 245.78K | |
| 25-Mar-20 4:43 PM View: | Jenne Kyle Chief Commercial Officer | Akcea Therapeutics, Inc. (AKCA) | 23-Mar-20 | Sale | 779 | $11.75 | $9,153.48 | (1%) 53.51K to 52.73K | |
| 25-Mar-20 4:42 PM View: | O'Dea Louis Chief Medical Officer | Akcea Therapeutics, Inc. (AKCA) | 23-Mar-20 | Sale | 3,198 | $11.75 | $37,578.70 | (5%) 64.8K to 61.6K | |
| 23-Mar-20 4:34 PM View: | Jenne Kyle Chief Commercial Officer | Akcea Therapeutics, Inc. (AKCA) | 19-Mar-20 | Grant | 16,800 | -- | -- | 46% 36.71K to 53.51K | |
| 23-Mar-20 4:32 PM View: | O'Dea Louis Chief Medical Officer | Akcea Therapeutics, Inc. (AKCA) | 19-Mar-20 | Grant | 16,800 | -- | -- | 35% 48.0K to 64.8K | |
| 23-Mar-20 4:29 PM View: | Patterson Joshua F. General Counsel | Akcea Therapeutics, Inc. (AKCA) | 19-Mar-20 | Grant | 3,780 | -- | -- | 34% 11.17K to 14.95K | |
| 23-Mar-20 4:22 PM View: | McDevitt Damien Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 19-Mar-20 | Grant | 55,200 | -- | -- | 28% 200.0K to 255.2K | |
| 23-Mar-20 4:35 PM View: | Howarth Alex G. Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 19-Mar-20 | Grant | 16,800 | -- | -- | 34% 50.0K to 66.8K | |
| 16-Jan-20 6:05 PM View: | O'Dea Louis Chief Medical Officer | Akcea Therapeutics, Inc. (AKCA) | 15-Jan-20 | Grant | 28,000 | -- | -- | 140% 20.0K to 48.0K | |
| 16-Jan-20 6:03 PM View: | MacLean Michael F Chief Financial Officer | Akcea Therapeutics, Inc. (AKCA) | 15-Jan-20 | Grant | 28,000 | -- | -- | 140% 20.0K to 48.0K | |
| 19-Dec-19 4:32 PM View: | Isis Pharmaceuticals Inc 10% Owner | Akcea Therapeutics, Inc. (AKCA) | 17-Dec-19 | Acquisition (other) | 6,873,340 | -- | -- | 10% 70.22M to 77.09M | |
| 04-Dec-19 4:08 PM View: | Howarth Alex G. Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 02-Dec-19 | Grant | 50,000 | -- | -- | 100% 0 to 50.0K | |
| 23-Oct-19 4:21 PM View: | Jenne Kyle Chief Commercial Officer | Akcea Therapeutics, Inc. (AKCA) | 21-Oct-19 | Grant | 25,000 | -- | -- | 213% 11.71K to 36.71K | |
| 30-Sep-19 5:52 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 26-Sep-19 | Option Exercise | 2,061,860 | $7.05 | $14,538,300.00 | 100% 0 to 2.06M | |
| 30-Sep-19 9:26 PM View: | Goldberg Jeff Marc Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 26-Sep-19 | Payment of Exercise | 268,111 | $16.64 | $4,461,370.00 | (63%) 424.74K to 156.63K | |
| 30-Sep-19 9:26 PM View: | Goldberg Jeff Marc Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 26-Sep-19 | Option Exercise | 421,432 | $6.96 | $2,932,750.00 | 12732% 3.31K to 424.74K | |
| 30-Sep-19 5:52 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 26-Sep-19 | Payment of Exercise | 1,383,710 | $16.64 | $23,025,000.00 | (67%) 2.06M to 678.15K | |
| 23-Sep-19 5:24 PM View: | MacLean Michael F Chief Financial Officer | Akcea Therapeutics, Inc. (AKCA) | 19-Sep-19 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 23-Sep-19 5:22 PM View: | McDevitt Damien Interim Chief Executive Office Director | Akcea Therapeutics, Inc. (AKCA) | 19-Sep-19 | Grant | 200,000 | -- | -- | 100% 0 to 200.0K | |
| 23-Sep-19 7:22 PM View: | O'Dea Louis Chief Medical Officer | Akcea Therapeutics, Inc. (AKCA) | 19-Sep-19 | Grant | 20,000 | -- | -- | 100% 0 to 20.0K | |
| 17-Jul-19 4:52 PM View: | Boyce Sarah President Director | Akcea Therapeutics, Inc. (AKCA) | 15-Jul-19 | Market Sale | 1,819 | $23.52 | $42,782.90 | (8%) 21.71K to 19.89K | 3% |
| 03-Jul-19 4:31 PM View: | Boyce Sarah President Director | Akcea Therapeutics, Inc. (AKCA) | 01-Jul-19 | Grant | 813 | $20.04 | $16,295.00 | 4% 20.89K to 21.71K | |
| 03-Jul-19 4:28 PM View: | Goldberg Jeff Marc Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 01-Jul-19 | Grant | 430 | $20.04 | $8,618.49 | 15% 2.88K to 3.31K | |
| 09-Apr-19 6:59 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 08-Apr-19 | Market Option Sale (Planned) | 1,787 | $32.17 | $57,480.30 | (100%) 1.79K to 0 | |
| 09-Apr-19 7:00 PM View: | Goldberg Jeff Marc Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 08-Apr-19 | Option Exercise | 20,000 | $6.48 | $129,600.00 | 694% 2.88K to 22.88K | |
| 09-Apr-19 7:00 PM View: | Goldberg Jeff Marc Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 08-Apr-19 | Market Option Sale (Planned) | 20,000 | $31.72 | $634,418.00 | (87%) 22.88K to 2.88K | |
| 09-Apr-19 6:59 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 08-Apr-19 | Option Exercise | 1,787 | $6.48 | $11,579.80 | 100% 0 to 1.79K | |
| 09-Apr-19 6:59 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 05-Apr-19 | Option Exercise | 30,000 | $6.48 | $194,400.00 | 100% 0 to 30.0K | |
| 09-Apr-19 6:59 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 05-Apr-19 | Market Option Sale (Planned) | 30,000 | $32.11 | $963,300.00 | (100%) 30.0K to 0 | |
| 09-Apr-19 7:00 PM View: | Goldberg Jeff Marc Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 05-Apr-19 | Option Exercise | 30,000 | $6.48 | $194,400.00 | 1042% 2.88K to 32.88K | |
| 09-Apr-19 7:00 PM View: | Goldberg Jeff Marc Chief Operating Officer | Akcea Therapeutics, Inc. (AKCA) | 05-Apr-19 | Market Option Sale (Planned) | 30,000 | $31.71 | $951,300.00 | (91%) 32.88K to 2.88K | |
| 02-Apr-19 4:20 PM View: | Isis Pharmaceuticals Inc 10% Owner | Akcea Therapeutics, Inc. (AKCA) | 29-Mar-19 | Acquisition (other) | 2,837,370 | -- | -- | 4% 67.38M to 70.22M | |
| 07-Mar-19 5:20 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 06-Mar-19 | Option Exercise | 18,386 | $6.48 | $119,141.00 | 100% 0 to 18.39K | |
| 07-Mar-19 5:20 PM View: | Soteropoulos Paula Chief Executive Officer Director | Akcea Therapeutics, Inc. (AKCA) | 06-Mar-19 | Market Option Sale (Planned) | 18,386 | $32.14 | $590,856.00 | (100%) 18.39K to 0 |
